1. Home
  2. VRDN

as of 12-12-2025 3:43pm EST

$32.44
$0.13
-0.40%
Stocks Health Care Medical Specialities Nasdaq

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Chart Type:
Time Range:
Founded: 2006 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 2.7B IPO Year: N/A
Target Price: $39.73 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.02 EPS Growth: N/A
52 Week Low/High: $9.90 - $33.34 Next Earning Date: 11-05-2025
Revenue: $70,789,000 Revenue Growth: 23340.07%
Revenue Growth (this year): 26477.48% Revenue Growth (next year): 6.23%

AI-Powered VRDN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 72.60%
72.60%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)

Buy
VRDN Oct 23, 2025

Avg Cost/Share

$22.00

Shares

454,545

Total Value

$9,999,990.00

Owned After

3,914,458

SEC Form 4

Share on Social Networks: